BIOMAT Database Logo BIOMAT Database Logo

[Effect of combination therapy with sulbactam/cefoperazone and amikacin in the treatment of infectious diseases accompanied by hematological disorders]. 1993

T Matsushima, and K Tamura, and K Okamoto, and E Kawada, and K Murayama, and T Maehara, and H Sadakata, and J Tamura, and M Sawamura, and K Morita
Third Department of Internal Medicine, Gunma University School of Medicine.

We studied the efficacy and safety of a combination therapy with sulbactam/cefoperazone (SBT/CPZ) and amikacin (AMK) on severe infections in the patients with hematological disorders. We administered SBT/CPZ and AMK to 65 patients and analyzed the result of 57 patients, except for 8 drop outs, for evaluation. The overall clinical efficacy of this combination therapy was 64.9% (excellent in 15 patients, good in 22 patients). Thirty seven patients had sepsis and suspected sepsis. The efficacy was 67.6% in these patients. The rate of improvement in the cases (18 patients) with neutrophil counts under 500/mm3 during the administration among 28 patients who had not responded to prior antibiotic treatment was 67.9%. Diarrhea was found in 1 patient as an apparent side effect likely related to this drug regimen. It appears that combination therapy of SBT/CPZ and AMK was a useful regimen in the treatment of infectious diseases complicated with hematological disorders.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002438 Cefoperazone Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections. Cefobid,Cefoperazon,Cefoperazone Sodium,Cefoperazone Sodium Salt,Céfobis,T-1551,T1551,Salt, Cefoperazone Sodium,Sodium Salt, Cefoperazone,Sodium, Cefoperazone,T 1551
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006402 Hematologic Diseases Disorders of the blood and blood forming tissues. Blood Diseases,Hematological Diseases,Blood Disease,Disease, Blood,Disease, Hematologic,Disease, Hematological,Diseases, Blood,Diseases, Hematologic,Diseases, Hematological,Hematologic Disease,Hematological Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T Matsushima, and K Tamura, and K Okamoto, and E Kawada, and K Murayama, and T Maehara, and H Sadakata, and J Tamura, and M Sawamura, and K Morita
[Clinical evaluation of combination therapy with sulbactam/cefoperazone and amikacin sulfate for infections associated with hematological disorders].
October 1993, The Japanese journal of antibiotics,
T Matsushima, and K Tamura, and K Okamoto, and E Kawada, and K Murayama, and T Maehara, and H Sadakata, and J Tamura, and M Sawamura, and K Morita
[A combined sulbactam/cefoperazone and amikacin therapy for the treatment of infections complicated with hematological diseases].
March 1993, The Japanese journal of antibiotics,
T Matsushima, and K Tamura, and K Okamoto, and E Kawada, and K Murayama, and T Maehara, and H Sadakata, and J Tamura, and M Sawamura, and K Morita
[Treatment with sulbactam/cefoperazone of severe infections in patients with hematological disorders].
August 1989, The Japanese journal of antibiotics,
T Matsushima, and K Tamura, and K Okamoto, and E Kawada, and K Murayama, and T Maehara, and H Sadakata, and J Tamura, and M Sawamura, and K Morita
Cefepime vs. cefoperazone/sulbactam in combination with amikacin as empirical antibiotic therapy in febrile neutropenia.
November 2018, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
T Matsushima, and K Tamura, and K Okamoto, and E Kawada, and K Murayama, and T Maehara, and H Sadakata, and J Tamura, and M Sawamura, and K Morita
Amikacin and cefoperazone/sulbactam alone or in combination against carbapenem-resistant Pseudomonas aeruginosa.
June 2018, Diagnostic microbiology and infectious disease,
T Matsushima, and K Tamura, and K Okamoto, and E Kawada, and K Murayama, and T Maehara, and H Sadakata, and J Tamura, and M Sawamura, and K Morita
[A combined consecutive therapy with fosfomycin and sulbactam/cefoperazone for bacterial infections associated with hematological diseases].
April 1995, The Japanese journal of antibiotics,
T Matsushima, and K Tamura, and K Okamoto, and E Kawada, and K Murayama, and T Maehara, and H Sadakata, and J Tamura, and M Sawamura, and K Morita
[Clinical evaluation of sulbactam/cefoperazone for severe infections associated with hematological disorders].
September 1991, The Japanese journal of antibiotics,
T Matsushima, and K Tamura, and K Okamoto, and E Kawada, and K Murayama, and T Maehara, and H Sadakata, and J Tamura, and M Sawamura, and K Morita
[Clinical evaluation of sulbactam/cefoperazone for severe infections associated with hematological disorders].
August 1992, The Japanese journal of antibiotics,
T Matsushima, and K Tamura, and K Okamoto, and E Kawada, and K Murayama, and T Maehara, and H Sadakata, and J Tamura, and M Sawamura, and K Morita
[Clinical and bacteriological efficiency of sulbactam/cefoperazone in gynecological infectious diseases].
October 1984, The Japanese journal of antibiotics,
T Matsushima, and K Tamura, and K Okamoto, and E Kawada, and K Murayama, and T Maehara, and H Sadakata, and J Tamura, and M Sawamura, and K Morita
[An evaluation of combination antibiotic therapy in infections with hematological disorders. Hyogo Cooperative Study Group of Infectious Diseases Complicating Hematological Disorders].
March 1991, The Japanese journal of antibiotics,
Copied contents to your clipboard!